Optimizing Detection and Interventions Against Rare Pre-existing Drug Resistance Mutations

优化针对罕见的预先存在的耐药突变的检测和干预措施

• 批准号: 10449299
• 负责人: Lawrence Kwong
• 金额: $ 66.46万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-21 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10449299
• 关键词: Behavior; Biological Models; Case Study; Cells; Clinical; Clinical Research; Clinical Treatment; Communicable Diseases; Consensus; Coupled; Cytomegalovirus; DNA Sequence Alteration; Data; Detection; Disease; Drug resistance; Early Diagnosis; Early Intervention; Early treatment; Evolution; Failure; Gene Frequency; Genes; Genetic Diseases; Graph; HIV; HIV/TB; Immunotherapy; Institution; Intervention; Knowledge; Lead; Malignant Neoplasms; Methods; Modeling; Multi-Drug Resistance; Mus; Mutation; Mutation Detection; Output; Patient-Focused Outcomes; Patients; Pharmaceutical Preparations; Pilot Projects; Population; Prevalence; Resistance; Resolution; Rewards; Risk; Sampling; Series; Technology; Testing; Time; Toxic effect; Treatment Efficacy; Treatment Failure; Tuberculosis; Virus; base; cost efficient; drug development; experience; genetic evolution; genetic variant; improved; melanoma; mouse model; novel; pre-clinical; pressure; prevent; resistance mechanism; resistance mutation; targeted treatment; therapeutic effectiveness; therapy outcome; tumor

Abstract Genetic mutations that cause drug failure are a major obstacle in many diseases including cancer, HIV, cytomegalovirus, and tuberculosis. Therapy-induced selection for resistance-conferring aberrations can arise either from new mutations or from those that pre-existed in a small subpopulation of the cells or viruses. This latter idea of pre-existing subclonal drug resistance is highly understudied across diseases, and there is no general clinical consensus on the best way to implement counter-resistance therapies. A large part of this is due to technical difficulties in detecting the subpopulations at both sufficient resolution and high enough throughput. Here, we leverage a novel high-sensitivity DNA mutation detection technology, multiplex blocker displacement amplification, and melanoma as a model system to study subclonal drug resistance for multiple genes inhundreds of pre-therapy patient samples. We will pair this clinical study with novel mouse models of subclonal resistance to optimize risk-reward strategies for counter-resistance therapies. Our preliminary data from melanoma patients are consistent with data from other cancers suggesting that very low allelic-frequency subclonal resistance mutations could pre-exist in over a third of patients' tumors. Therefore, our overall approach is aimed at determining how to best treat patients with potential subclonal resistance, first by improving mutation detection in patients and second by determining which mutation-positive patients would most benefit from optimally-timed counter-resistance interventions. Although we start with melanoma as a model system, our approach will serve as a broadly-applicable blueprint for recognizing and overcoming pre-existing subclonal resistance.

摘要